Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CYP2C9 encodes a member of the cytochrome P450 superfamily of enzymes. Additionally we are shipping CYP2C9 Antibodies (58) and CYP2C9 Proteins (4) and many more products for this protein.
Showing 5 out of 22 products:
Data suggest that SNPs in CYP2C9 (*3, I359L; *30, A477T) that reduce catalytic activity of CYP2C9 also alter interaction with antihypertensive drug losartan; I359L substitution located far from active site remarkably alters residue side chains near active site and access channel, whereas the T477 substitution illustrates hydrogen-bonding interaction with reoriented side chain of Q214.
SNP rs4918758 of CYP2C9 showed a suggestive association with decreased risk of coronary heart disease.
CYP2C9*31075AC genotype with combined alcohol and nevirapine usage indicated a risk for development of antiretroviral-associated hepatotoxicity
CYP2C9 polymorphisms showed no effect on PC doses. Similar findings were observed in the initiation phase of PC therapy. High complications rates under PC therapy were observed particularly at the beginning.
Genetic variants of CYP2C9/VKORC1 (show VKORC1 ELISA Kits) and age are significant determinants of the maintenance dose of warfarin in patients with atrial fibrillation/valve replacement.
CYP2C9*3 polymorphism genotype and allele frequency were not statistically different between the case and control Ankylosing Spondylitis groups (P>0.05). the efficacy of NSAID in treatment of AS and COX-2 (show COX2 ELISA Kits) gene -1290A/G and -1195G/A polymorphism were associated (all P<0.05), but it is not associated with CYP2C9 *3 polymorphism (all P>0.05).
polymorphisms c.98T>C in the UGT1A9 (show UGT1A9 ELISA Kits) and c.1075A>C in the CYP2C9 genes did not affect the pharmacokinetic profile of propofol
Possession of CYP2C9*2 and/or CYP2C9*3 allele variants is associated with lower time of international normalized ratio (INR (show INSR ELISA Kits)) in the therapeutic range (TTR (show TTR ELISA Kits)) values and warfarin dose variations in aortic valve replacement patients, the latter affected also by VKORC1 (show VKORC1 ELISA Kits) c.-1693G>A polymorphism
Three SNPs (CYP2C9 *2, *3 and VKORC1 (show VKORC1 ELISA Kits) c.-1639G > A) were genotyped by electrochemical detection using a sandwich-type format that included a 3' short thiol capture probe and a 5' ferrocene-labeled signal probe.
This study was aimed to describe the distribution of CYP2C9 and CYP2C19 (show CYP2C19 ELISA Kits) alleles and haplotypes in four Mestizo populations from Western Mexico. Frequencies ranged from 2.2-3.0% and 4.8-8.9% for CYP2C9*3 and CYP2C9*2 alleles, respectively, and 5.4-12.0% for CYP2C19 (show CYP2C19 ELISA Kits)*2, whereas the CYP2C19 (show CYP2C19 ELISA Kits)*3 allele was not found.
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by rifampin. The enzyme is known to metabolize many xenobiotics, including phenytoin, tolbutamide, ibuprofen and S-warfarin. Studies identifying individuals who are poor metabolizers of phenytoin and tolbutamide suggest that this gene is polymorphic. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24.
cytochrome P-450 S-mephenytoin 4-hydroxylase
, cytochrome P-450MP
, cytochrome P450 2C9
, cytochrome P450 PB-1
, flavoprotein-linked monooxygenase
, microsomal monooxygenase
, xenobiotic monooxygenase